Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Application of leflunomide and teriflunomide to leukemia treatment

A technology of teriflunomide and leflunomide is applied in the application field of leflunomide and teriflunomide in the treatment of leukemia, and can solve the problems of high recurrence rate and low long-term disease-free survival rate.

Inactive Publication Date: 2018-11-02
EAST CHINA UNIV OF SCI & TECH
View PDF1 Cites 1 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, due to the high recurrence rate and low long-term disease-free survival rate of AML, in order to effectively improve the prognosis of AML patients, it is imperative to develop new AML therapeutic drugs with high efficiency and low toxicity.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of leflunomide and teriflunomide to leukemia treatment
  • Application of leflunomide and teriflunomide to leukemia treatment
  • Application of leflunomide and teriflunomide to leukemia treatment

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0046] The inventors have detected leflunomide, teriflunomide and buquina and anthracyclines (daunorubicin, demethoxydaunorubicin or mitoxantrone) and cytarabine on leukemia cells. As shown in Table 1, HL60 and NB4 are acute promyeloid leukemia cells; THP1, SIG-M5, AML2, AML5, MONOMAC6, AML3, U937, Molm13, and Molm14 are acute myeloid leukemia cells; Jurkat is acute myeloid leukemia cells; Lymphocytic leukemia; K562 cells are chronic myeloid leukemia cells; MEC1 and MO1043 are chronic lymphocytic leukemia cells. The results are shown in Table 1.

[0047] Table 1. The half maximal inhibitory concentration of each compound on leukemia cell lines

[0048]

[0049]

[0050] As can be seen from the test results, leflunomide and teriflunomide have a positive effect on acute myeloid leukemia (including acute promyelocytic leukemia), acute lymphoblastic leukemia, chronic myeloid leukemia, and chronic lymphocytic leukemia cell lines. Inhibitory effect, wherein the inhibitory ef...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention discloses application of leflunomide and teriflunomide or derivatives or pharmaceutically acceptable salt thereof to preparation of medicines for treating leukemia. The leflunomide and the teriflunomid have remarkable inhibition effect on the leukemia comprising acute lymphoblastic leukemia (ALL), acute myelocytic leukemia (AML), chronic granulocytic leukemia, chronic lymphocytic leukemia and the like; and new material basis is laid for the development of the medicines for treating leukemia.

Description

technical field [0001] The present invention relates to the application of leflunomide and teriflunomide in the preparation and treatment of leukemia medicine and leukemia treatment; specifically, the present invention relates to the application of leflunomide and teriflunomide in the preparation and treatment of non-acute myeloid leukemia (including But not limited to acute promyelocytic leukemia), acute lymphocytic leukemia, chronic myeloid leukemia and chronic lymphocytic leukemia drugs and in the treatment of acute myeloid leukemia (including but not limited to acute promyelocytic leukemia), acute Application in lymphocytic leukemia, chronic myeloid leukemia and chronic lymphocytic leukemia. Background technique [0002] Leukemia is a kind of clonal malignant disease with abnormal hematopoietic stem cells. The leukemia cells in its clones lose the ability to further differentiate and mature and stagnate at different stages of cell development. In the bone marrow and ot...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K31/42A61K31/277A61P35/02
CPCA61K31/277A61K31/42A61K2300/00
Inventor 李洪林陈卓赵振江
Owner EAST CHINA UNIV OF SCI & TECH
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com